Industry News
Pharmaceutical Industry News
At the final analysis of the phase…
At the final analysis of the phase 3 Applause-IgAN trial, Novartis’ complement factor B inhibitor Fabhalta showed that it can slow kidney function decline and IgAN progression, the company said. Novartis plans to leverage the
Eli Lilly hopes its latest overall…
Eli Lilly hopes its latest overall survival win could increase the adoption of Verzenio and, by extension, the entire CDK4/6 inhibitor class in early breast cancer.
A well-established diabetes drug…
A well-established diabetes drug alleviated brain inflammation in a female mouse model of multiple sclerosis, suggesting the long-used medicine could be repurposed to combat MS in people with female sex chromosomes, who are disproportionately affected
America Is Heavily Reliant on China for Raw Materials in Medicines
A new analysis found that nearly 700 drugs approved for use in the United States depend on chemicals solely produced in China.
Veradermics will use the funding…
Veradermics will use the funding to support further phase 3 development for its extended-release formulation of oral minoxidil, a decades-old hypertension treatment that's commonly used off-label for hair loss.
Following a strong early showing…
Following a strong early showing of Tecvayli and Darzalex Faspro in newly diagnosed multiple myeloma patients last month, Johnson & Johnson is making the case for its oncology cocktail as a potential second-line therapy for
In separate announcements on…
In separate announcements on Wednesday, a pair of agencies shared business updates both aimed at leveling up their respective abilities to connect with doctors and patients—as standard healthcare marketing practices are being upended by AI
With sales of potential…
With sales of potential blockbuster Lokelma scaling up, AstraZeneca is bolstering its production of the hyperkalemia treatment with a $445 million injection of funds. The investment will increase the capabilities of AZ’s manufacturing facility in
Through the agreement, Scynexis…
Through the agreement, Scynexis will oblige GSK's request to wind down its phase 3 study of antifungal med Brexafemme in invasive candidiasis, which it had restarted after the FDA lifted a clinical hold earlier this
In addition to substantial spray…
In addition to substantial spray drying capacity, new CDMO Codis says it's also equipped to handle commercial-scale work on amorphous solid dispersions, particle engineering and finished dose manufacturing for pharma, consumer health and over-the- counter
GSK’s study evaluated the…
GSK's study evaluated the tolerability and acceptability of its long-acting pre-exposure prophylaxis drug Apretude compared with Gilead's rival Yeztugo.
After Rezdiffra’s approval and…
After Rezdiffra’s approval and Wegovy’s label expansion, the race is on in metabolic dysfunction-associated steatohepatitis. M&A deals totaling more than $10 billion in recent months show major pharma players still see sizable opportunity in the
Just a few months after surfacing…
Just a few months after surfacing at Orca Bio following his early 2025 departure from Legend Biotech, Steve Gavel has taken on the chief commercial officer role at yet another cell therapy biotech.
In a new episode of The Top Line,…
In a new episode of The Top Line, Salesforce’s president of regulated industries explains why life science companies should embrace digital transformation and rethink engagement with patients and providers.
The positive readout could move…
The positive readout could move Tukysa, which has been used for second-line, HER2-positive breast cancer, into the earlier, first-line maintenance setting.
With two Trump administration drug…
With two Trump administration drug pricing deals in the books and more likely on the way, the U.S. policy environment could soon stabilize for many Big Pharma companies. That put Johnson & Johnson in an
As BioNTech works to establish a…
As BioNTech works to establish a production footprint for mRNA vaccines in Africa, two EU groups have offered financial backing to the company's efforts.
Opioid Deaths Suddenly Dominate a Governor’s Race. Here’s What We Know.
Representative Mikie Sherrill, a New Jersey Democrat, said a firm once owned by her Republican opponent, Jack Ciattarelli, spread misinformation about opioids. His campaign has threatened to sue her for defamation.
W.H.O. Warns of Sharp Increase in Drug-Resistant Infections
The U.N. health agency found that one in six infections worldwide was resistant to the most commonly available antibiotics.
The FDA has tagged Novo Nordisk’s…
The FDA has tagged Novo Nordisk's newly acquired manufacturing facility in Indiana with an official action indicated label, which is the most severe of the three inspection classifications issued by the agency.